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Telomeres are specialized structures located at the ends of eukary-
otic chromosomes that help to stabilize chromosomes during
replication (Muller, 1938; McClintock, 1941; Greider, 1994). In
humans, these regions are predominantly composed of the
sequence TTAGGG iterated many times to give a total of about
5–15 kbp (Moyzis et al, 1988; Morin, 1989). In normal human
cells, DNA polymerase is unable to replicate the ends of linear
DNA, and each cell division results in the loss of some 50–200
nucleotide from the ends of chromosomes (Allsop et al, 1995).
During the lifespan of a normal somatic cell, successive cell divi-
sion will result in gradual shortening of the telomeres until the
chromosomes become critically short. This can lead to destabiliza-
tion and loss of chromosomes followed by senescence and cell
death. This telomere shortening has been suggested to be a
‘mitotic clock’ and a cellular mechanism whereby cells count their
divisions (Harley, 1991).
The stabilization of telomere length is thought to be a critical
molecular event in the multistep pathway to cellular transforma-
tion and immortalization (Rhyu, 1995). Telomerase, a ribonucleo-
protein, is a key enzyme involved in the stabilization of telomeres
in transformed cells in culture as well as tumour cells in vivo.
Telomerase is capable of adding telomeric sequences (TTAGGG
hexameric repeats) to the ends of chromosomes and, thereby,
halting the erosion of chromosome with each cell division (Morin,
1989). Using the highly sensitive telomeric repeat amplification
procedure (TRAP) (Piatyszek et al, 1995), telomerase activity has
been detected in a large majority of immortalized cells and those
derived from tumour biopsies (Kim et al, 1994; Bacchetti and
Counter, 1995; Holt et al, 1996). In addition, telomerase activity
has been detected in somatic cells with renewal capacity, such as
germline cells of the testis and ovary, endometrial cells (Kyo et al,
1997), proliferative basal cells of the epidermis (Harle-Bachor and
Boukamp, 1996) and haemopoietic cells (Broccoli et al, 1995).
Skin cancer is the most common cancer in humans, and there is
increasing evidence that solar ultraviolet radiation is a major aeti-
ological factor (IARC, 1992). The precise molecular events in skin
carcinogenesis are numerous and complicated. However, inactiva-
tion of the p53 tumour-suppressor gene (TSG) is common in non-
melanoma skin cancer (Brash et al, 1991), and inactivation of the
p16 TSG is thought to be a critical step in melanoma development
(Flores et al, 1996). In addition, evidence suggests that activation
of the telomerase enzyme is a pivotal step in the development of
all forms of skin cancer. In fact, telomerase activity has been
observed in 75–85% of all forms of skin cancer and has also been
observed in normal skin exposed to solar ultraviolet radiation
(Taylor et al, 1996; Ueda et al, 1997). Thus, it is evident that stabi-
lization and maintenance of telomeres is a central event in cellular
immortalization and carcinogenesis. Moreover, evidence strongly
suggests that telomerase activation is largely responsible for
telomere stability (Rhyu, 1995).
However, it has been consistently demonstrated that, overall,
some 15–20% of all tumour biopsy samples, including skin
Telomerase activity in melanoma and non-melanoma
skin cancer
CN Parris1, S Jezzard1, A Silver2, R MacKie3, JM McGregor4 and RF Newbold1
1Department of Biology and Biochemistry, Brunel University, Cleveland Road, Uxbridge, Middlesex UB8 3PH, UK; 2National Radiological Protection Board,
Chilton, Didcot, Oxon, UK; 3Department of Dermatology, Robertson Building, University of Glasgow, Glasgow G12 8QQ, UK; 4Department of Photobiology, 
St John’s Institute of Dermatology, St. Thomas’s Hospital, London SE1 7EH, UK
Summary Telomeres are specialized structures consisting of repeat arrays of TTAGGGn located at the ends of chromosomes. They are
essential for chromosome stability and, in the majority of normal somatic cells, telomeres shorten with each cell division. Most immortalized
cell lines and tumours reactivate telomerase to stabilize the shortening chromosomes. Telomerase activation is regarded as a central step in
carcinogenesis and, here, we demonstrate telomerase activation in premalignant skin lesions and also in all forms of skin cancer. Telomerase
activation in normal skin was a rare event, and among 16 samples of normal skin (one with a history of chronic sun exposure) 12.5% (2 out of
16) exhibited telomerase activity. One out of 16 (6.25%) benign proliferative lesions, including viral and seborrhoeic wart samples, had
telomerase activity. In premalignant actinic keratoses and Bowen’s disease, 42% (11 out of 26) of samples exhibited telomerase activity. In the
basal cell carcinoma and cutaneous malignant melanoma (CMM) lesions, telomerase was activated in 77% (10 out of 13) and 69% (22 out of
32) respectively. However, only 25% (3 out of 12) of squamous cell carcinomas (SCC) had telomerase activity. With the exception of one SCC
sample, telomerase activity in a positive control cell line derived from a fibrosarcoma (HT1080) was not inhibited when mixed with the
telomerase-negative SCC or CMM extracts, indicating that, overall, Taq polymerase and telomerase inhibitors were not responsible for the
negative results. Mean telomere hybridizing restriction fragment (TRF) analysis was performed in a number of telomerase-positive and -
negative samples and, although a broad range of TRF sizes ranging from 3.6 to 17 kb was observed, a relationship between telomerase
status and TRF size was not found.
Keywords: skin cancer; telomerase; telomeric repeat amplification procedure; telomere length
47
British Journal of Cancer (1999) 79(1), 47–53
© 1999 Cancer Research Campaign
Received 19 December 1997
Revised 11 June 1998
Accepted 16 June 1998
Correspondence to: CN Parriscancer, and a significant number of immortalized cell lines in
culture do not have detectable telomerase activity. Therefore, in a
subpopulation of cancers at least, acquisition of presumably
unlimited growth potential is achieved without activation of
telomerase. This critical observation suggests that other mecha-
nisms of telomere maintenance exist, given that telomere mainte-
nance is essential for cellular immortalization and cancer.
Without doubt, the telomerase enzyme is a central mechanism
of telomere maintenance, however, pathways have been identified
that appear to be independent of telomerase. The Saccharomyces
cerevisiae Est1 mutant is able to maintain constant telomere
structure by a recombination pathway using subtelomeric elements
(Lundblad and Blackburn, 1993). In addition, approximately one-
third of in vitro immortalized cell lines have no detectable telo-
merase activity, but have very long telomeres (Bryan et al, 1995).
This suggests that the telomeres can be maintained by a telo-
merase-independent pathway, a mechanism referred to as the ALT
pathway (alternative lengthening of telomeres) (Murnane et al,
1994; Bryan et al, 1997a). ALT has been detected in a number of
human cell lines derived from tumours, in a small number of
tumour biopsy samples (Bryan et al, 1997b), and also in cells
transformed with oncogenic viruses (Bryan et al, 1995). The
precise molecular pathway of the ALT mechanism is hitherto
unknown, but it does not appear to involve (at least transient) telo-
merase activity. Telomerase-negative cell lines have been
observed increasing the length of their telomeres without prior
telomerase activity (Rogan et al, 1995). Moreover, the ALT mech-
anisms do not involve the transposition of other elements such as
transposons to the telomeres, as seen in Drosophila because the
telomeres in these cells hybridize strongly with TTAGGGn probes
(Bryan et al, 1995).
Furthermore, it has been recently demonstrated in transgenic
mice, which are deleted for the RNA component of the telomerase
enzyme (mTR), that although telomerase was central for telomere
maintenance it was not required for establishment of continuous
cell lines, oncogenic transformation or tumour formation in mice
(Blasco et al, 1997).
Therefore, it is clear that telomere maintenance in some
immortal cell lines and tumour samples can occur by molecular
mechanisms that do not involve the telomerase enzyme, although
the precise events have yet to be described.
In this study, we demonstrate telomerase activity in premalig-
nant lesions and skin exposed to solar UV irradiation. We also
present evidence implicating the activation of telomerase in both
melanoma and non-melanoma tumours of the skin. In addition, a
collection of squamous cell carcinomas with no detectable telo-
merase activity has been identified. The telomere length of some
telomerase-positive and -negative skin cancer samples was exam-
ined to determine whether there is a relationship between telomere
length and telomerase activity.
MATERIALS AND METHODS
Tissue samples
Thirty-two cutaneous malignant melanoma tumour samples were
obtained from the Department of Dermatology, University of
Glasgow, UK. All samples with the exception of one primary
lesion, were derived from lymph node metastases (clinical stage 3
disease). In addition, the single primary tumour was accompanied
by two metastatic lesions from the same individual. The remaining
83 tissue samples were obtained by 6-mm punch biopsy from St.
John’s Institute of Dermatology, London, UK. The non-melanoma
squamous cell carcinoma (SCC) and basal cell carcinoma (BCC)
samples were of moderate to well-differentiated nodular lesions.
The collected tissues were subject to histopathological examina-
tion to verify the diagnosis in each case. Tissues were snap frozen
in liquid nitrogen and stored at –80°C until use. The samples are
listed in Table 1.
Extract preparation
Samples were removed from –80°C storage, and after detailed
visual inspection, were carefully trimmed to remove excess
normal tissue. A longitudinal section of the tissue sample was first
prepared, thus ensuring that all cell types within the sample were
included in the extract preparation. The section was then carefully
sliced on 100-cm Petri dishes using sterile disposable scalpels and
homogenized with about 10–12 strokes in a Dounce homogenizer
containing ice-cold lysis buffer [10 mM tris-HCl, pH 7.5, 1 mM
magnesium chloride, 1 mM EGTA, 0.5% (w/v) CHAPS, 10% (v/v)
glycerol, 0.1 mM PMSF and 5 mM b-mercaptoethanol]. After a
further 30 min incubation on ice, lysates were transferred to 1.5-ml
centrifuge tubes and spun at 14 000 g for 30 min at 4°C. The
supernatants were snap frozen and stored at –80°C. Protein
concentrations were determined using the Coomassie protein 
kit (Pierce) and aliquots were prepared at a concentration of 
0.5 mg ml–1 protein.
Telomerase assay
Telomerase activity was determined using a two-stage assay modi-
fied from that of Kim et al. (1994) Assay tubes consisted of 1 ml
CX primer (0.1 mg) (5¢-CCCTTACCCTTACCCTTACCCTAA-3¢)
lyophilized under a wax barrier (Ampliwax PCR gem 100, Perkin-
Elmer), above which a reaction mixture containing 20 mM tris-
HCl, pH 8.3, 1.5 mM magnesium chloride, 68 mM potassium
chloride, 0.05% Tween-20, 1 mM EGTA, 50 mM dNTPs, 0.1 mg of
TS primer (5¢-AATCCGTCGAGCAGAGTT-3¢), 0.2 mCi dCTP
and 0.2 mCi TTP (3000 Ci mmol–1) (ICN Flow), 0.5 mg T4g32
single-stranded binding protein (Pharmacia), 2 U Taq Polymerase
(Promega) and 1 mg of extract was added. Included in each assay
was 5 ag of an internal telomerase amplification standard
(ITAS) (a gift from L Gollahon) to detect false-negative tumour
samples containing Taq inhibitors. Extension of the TS primer by
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Table 1 Summary of telomerase activity in skin biopsy samples
Sample type Number Positive
Normal skin 16 2
Benign proliferative lesions
Viral/seborrhoeic wart 16 1
Premalignant SCC lesions
Bowen’s disease 4 1
Actinic keratoses 22 10




Total 115 49telomerase was conducted at room temperature and the reaction
mixture was heated to 90°C for 90 s. Polymerase chain reaction
(PCR) conditions were as follows: 94°C for 30 s, 50°C for 40 s
and 72°C for 50 s for 31 cycles. Telomerase products were sepa-
rated on 10% non-denaturing polyacrylamide gels and visualized
using a PhosphoImager (Molecular Dynamics).
Alkaline phosphatase estimation
The viability of the protein components of extracted biopsy
samples was estimated by determining the activity of alkaline
phosphatase as previously described (Piatyszek et al, 1995). In
brief, 10-ml aliquots of protein extract in TRAP lysis buffer
containing 20–30 mg protein was added to 200 ml p-nitrophenyl
phosphate substrate solution and incubated for 30 min at 37°C.
The reaction was stopped with 2 ml 0.005 N sodium hydroxide,
after which the absorbance at 405 nm was read. Concentrated
hydrochloric acid (40 ml) was added to remove the colour due to p-
nitrophenol, after which the residual absorbance at 405 nm was
subtracted to give absorbance attributable to alkaline phosphatase.
Telomerase inhibitors
To exclude the possibility of false-negative TRAP assay results, we
performed mixing experiments to test for the presence of telom-
erase inhibitors introduced during extract preparation. Extracts
derived from skin sample biopsies, with or without telomerase
activity, were mixed in a 1:1 ratio with extracts prepared from a
telomerase-positive fibrosarcoma cell line HT1080. The mixtures
were subjected to TRAP analysis as described previously.
TRAP sensitivity experiments
The sensitivity of our TRAP assay was routinely determined by
using the telomerase-positive HT1080 cell extract. Dilutions from
1 to 1000 cell equivalents of extract were made, and at each dilu-
tion telomerase activity was determined with the TRAP assay.
TRAP assay sensitivity was deemed sufficient if telomerase
activity in ten cell equivalents was detected.
Telomere length analysis
Tumour biopsy samples were examined macroscopically and
trimmed of excess tissue to leave an homogeneous sample of
tumour tissue. High molecular weight DNA was then prepared by
isolating the nuclei. Briefly, nuclei were isolated by 10–12 strokes
of Dounce homogenization using a loose-fitting type B pestle in
ten volumes of ice-cold nuclear extraction buffer [250 mM sucrose,
10 mM tris HCl, pH 8, 10 mM magnesium chloride, 1 mM EGTA,
10 mg ml–1 bovine serum albumin (BSA), 0.2 mM PMSF, 1 mM
DTT]. Supernatants were recovered after centrifugation at 
900 r.p.m. for 5 min and 1:7 vol of 80% glycerol in nuclear extrac-
tion buffer was added. Nuclei were pelleted at 3500 r.p.m. for 15
min and washed with a further 15 ml of nuclear extraction buffer.
Nuclei were counted and approximately 1´106 were embedded in
1% low gelling temperature agarose (Flowgen). Agarose plugs
were then processed according to Anand (1986) and the DNA in
plugs digested with 80 U Hinf1 for 4 h at 37°C, as described previ-
ously (Silver et al, 1991).
DNA was fractionated though a 1% agarose gel in 0.5 ´ Tris-
borate-EDTA buffer by pulsed field gel electrophoresis (PFGE)
using a CHEF mapper system (Biorad). The conditions for the
PFGE were set to allow resolution of DNA fragments ranging
from 2 to 50 kb using the autoalgorithm according to the manufac-
turer’s instructions. DNA standard markers were obtained from
BRL, Life Technologies. DNA was visualized by ethidium
bromide staining and transferred to Hybond N+ membranes
(Amersham) overnight using 0.4 N sodium hydroxide. Membranes
were hybridized overnight to a g-32P 5¢ end-labelled telomeric
probe [g-32P-(TTAGGG)4] at 48°C. Membranes were washed four
times in 4´SSC, 0.1% sodium dodecyl sulphate (SDS), at 48°C 
for 15 min and once in 2´SSC, 0.1% SDS, at room temperature 
for 30 min. Hybridized membranes were then autoradiographed
overnight using intensifying screens. Mean telomere lengths of the
samples were estimated by densitometric scanning of auto-
radiographs using a Biorad GS700 imaging densitometer and then
calculated as detailed in Hastie et al (1990).
Mean telomere lengths were determined as described by Hastie
et al. (1990). Briefly, autoradiographs were analysed by an auto-
matic autoradiographic scanner (Biorad). The optical density
reading under the peak was integrated and the mean determined.
RESULTS
Telomerase activity
Normal skin and benign cutaneous lesions
Using the TRAP protocol, telomerase activity was determined in a
total of 115 skin samples, comprising normal skin, cutaneous viral
warts, seborrhoeic keratoses, premalignant keratoses, squamous
and basal cell carcinomas and cutaneous malignant melanomas.
The samples and corresponding telomerase status are summarized
in Table 1. The majority (14 out of 16) of normal skin samples
were negative for telomerase activity. One of the normal skin
samples, which proved telomerase positive, was from chronically
sun-exposed skin, consistent with previous findings demonstrating
transient telomerase activation associated with solar UV exposure
(Taylor et al, 1996; Ueda et al, 1997).
A total of 16 samples derived from viral and seborrhoeic warts
were analysed for telomerase activity, and only one (6.25%) of the
samples was positive. The other 15 samples had no detectable
telomerase activity.
Premalignant lesions
Premalignant lesions, including Bowen’s disease and actinic
keratoses, were examined to test whether telomerase was activated
at this stage in skin carcinogenesis. Ten out of 22 samples (45%)
assayed for telomerase activity were positive. The data indicated
that telomerase activity was detectable in a variety of non-malig-
nant proliferative disorders and, moreover, that telomerase was
also activated in substantial numbers of premalignant lesions of
squamous cell carcinoma of the skin.
Invasive melanoma and non-melanoma skin cancers
Thirteen BCC, 12 SCC and 32 cutaneous malignant melanoma
(CMM) samples were analysed for the presence of telomerase
activity. The majority of BCCs (10 out of 13; 77%) showed telo-
merase activity, results consistent with previous observations
(Taylor et al, 1996; Ueda et al, 1997), but only three SCC samples
had detectable telomerase activity (3 out of 12; 25%). This result is
in contrast to the previous studies of Taylor et al (1996) and Ueda
et al (1997), who found telomerase activity in 75–85% of SCCs.
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protein concentrations, repeat TRAP assays were performed at
several different protein extract dilutions (0.25, 0.5, 1.0 and
2.0 mgm l –1). However, at all concentrations of extract, 9 out of 12
(75%) of the SCC samples proved to be telomerase negative.
In contrast, telomerase activation proved to be a more consistent
event in CMM, with 69% (22 out of 32) demonstrating enzyme
activity. However, a significant number (10 out of 32) still did not
give positive TRAP results. Indeed, of the negative CMM
samples, three biopsies were obtained from the same individual
and included a primary and two independent metastatic lesions
biopsied from distant sites and all failed to show telomerase acti-
vation. This result clearly demonstrates that in some cases of
advanced CMM, including metastatic lesions, there is a failure to
activate the telomerase enzyme.
Telomerase inhibition experiments
In view of the significant number of telomerase-negative SCC,
CMM and, to a lesser extent, BCC samples, it was possible that
telomerase or Taq polymerase inhibitors were present in the
protein extracts. Such inhibitors would obviously create inaccu-
rate false-negative results. To eliminate this possibility, negative
extracts were mixed with a telomerase-positive control protein
extract derived from the HT1080 fibrosarcoma cell line. As a
consequence, inhibitors of the reaction would be identified by the
disappearance or reduction in intensity of the telomerase ladder
and/or ITAS band after PCR and electrophoresis.
Telomerase-negative SCC, CMM and BCC protein extracts were
mixed in a 1:1 ratio with the telomerase-positive HT1080 cell
extract. In addition, mixing of HT1080 extract with telomerase-
negative normal skin and BSA was also performed. Of the seven
SCC samples used in the mixing experiments, only one appeared to
have a Taq polymerase inhibitor present, as demonstrated by the
lack of an ITAS band and no telomerase ladder (Figure 1A, lane 2).
None of the telomerase-negative normal skin samples contained
either a Taq or telomerase inhibitor (Figure 1B, lanes 9 and 10)
and, thus, were bona fide telomerase-negative samples.
Moreover, the addition of a non-specific protein (BSA) to the
HT1080 extract failed to inhibit or to reduce telomerase activity
(Figure 1, lane 11).
Telomerase/Taq inhibition experiments were also performed
with extracts from three telomerase-negative CMM samples, in
which telomerase activity was not detected (Figure 1B). Similar to
the SCC samples, the CMMs contained neither a telomerase or
Taq polymerase inhibitor and, hence, were taken to be genuine
telomerase-negative CMM tumours.
In summary, the lack of telomerase activity in the SCC,
CMM and BCC cancer samples was not due to inhibitors
present in the protein samples. Finally, the alkaline
phosphatase activity of the telomerase-negative samples was
not different from protein extracts derived from equivalent
telomerase-positive samples.
Sensitivity of the TRAP assay – dilution experiments
To exclude the possibility that an overall lack of TRAP assay
sensitivity was responsible for negative results, dilution experi-
ments were routinely performed to determine the minimum
number of cell equivalents required to give a positive TRAP
signal. Using the HT1080 fibrosarcoma cell line, we were able to
routinely detect telomerase activity in a minimum of ten cell
equivalents (Figure 2, lane 3). However, maximum telomerase
activity was normally observed in 250–750 cell equivalents
(Figure 2, lanes 6–8). In view of the finding that we were able to
detect telomerase activity in as little as ten cell equivalents, we
were satisfied that our assay was of sufficient sensitivity for these
experiments.
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Figure 1 (A) Inhibition of telomerase activity by telomerase-negative biopsy samples. Protein extracts were
mixed in a 1:1 ratio with the telomerase-positive HT1080 cell extract. Lanes 1 and 3–7, telomerase-negative
SCC samples which do not inhibit the telomerase activity of the positive HT1080 extract; lane 2, telomerase-
negative SCC which does inhibit the positive HT1080 extract; lane 8, telomerase-negative BCC sample; lanes
9 and 10, telomerase-negative normal skin (extracts do not inhibit the HT1080 telomerase activity); lane 11,
BSA; lane 12, telomerase activity of the HT1080 extract alone (positive control); lane 13, lysis buffer (negative
control). (B) Failure of the telomerase negative extracts of CMM to inhibit the telomerase-positive HT1080
extracts in a mixing experiment. Lanes 1–3, telomerase-negative CMM extracts mixed with HT1080 extract in
a 1:1 ratio; lane 4, BSA; lane 5, HT1080 extract (positive control); lane 6, lysis buffer (negative control)Mean telomere restriction fragment size
Telomere size was estimated in six telomerase-negative and two
telomerase-positive SCC samples, two telomerase-positive CMM
and a normal skin sample (Figure 3A and B and Figure 4). A wide
range of telomere hybridizing restriction fragment (TRF) size was
observed, suggesting that there did not appear to be a relationship
between telomerase activity and TRF size for any of these
samples. For the telomerase-negative SCCs, the mean TRF size
ranged from 3.6 to 11 kb, and two telomerase-positive SCCs
exhibited a similar size diversity with one sample of 17 kb and
another of 4.1 kb. Also, the two telomerase-positive CMM
samples had TRF sizes of 4.5 and 14.2 kb respectively.
DISCUSSION
We have investigated the activity of the ribonucleoprotein telom-
erase in a large, random collection of different skin lesions, and
examined the relationship between malignancy in this tissue and
telomerase reactivation.
In normal skin, only 2 out of 16 (12.5%) had detectable
telomerase activity. One example was observed in chronically sun-
exposed skin, in accord with previous data, demonstrating telom-
erase reactivation and prior solar UV exposure (Taylor et al, 1996;
Ueda et al, 1997). Although the infiltration of lymphocytes into the
skin may cause transient telomerase activity in skin biopsy
samples (Broccoli et al, 1995), in this study none of the normal
skin samples were observed with lymphocytic infiltration by
histopathological examination. However, it should be stated that
telomerase activity in normal skin samples is not without prece-
dence because telomerase activity has been demonstrated in some
normal samples, which could be attributed to proliferating basal
cells of the epidermis (Harle-Bachor and Boukamp, 1996).
Telomerase activity was similarly rare in 16 benign proliferative
skin lesions, namely the viral and seborrhoeic wart samples (Table
1). Of the premalignant squamous cell lesions (actinic keratoses
and Bowen’s disease), a significant number were found to be
telomerase positive, suggesting that telomerase reactivation may
occur as a preinvasive event in skin carcinogenesis.
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Figure 2 Sensitivity of the TRAP assay. A representative example of the
dilution experiment in which telomerase-positive HT1080 extract was diluted
from 1000 to 1 cell equivalents and the corresponding telomerase activity
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Figure 3 Southern blot of telomere-hybridizing restriction fragments derived
from telomerase-positive and -negative SCC samples and telomerase-
positive CMM samples. (A) Lanes 1–5, telomere-hybridizing restriction
fragments derived from telomerase-negative SCC samples. (B) Lanes 6 and
7, telomerase-positive SCC samples and lanes 8 and 9 telomerase-positive
CMM samplesIn the malignant skin condition SCC, telomerase activity was
shown by Taylor et al (1996) and Ueda et al (1997) to be detectable
in some 75–85% of samples assayed. In contrast, the data presented
here showed only 25% of SCC samples with discernible telomerase
activity. Considerable care was taken to ensure that our observa-
tions were not artefactual, particularly in view of Taylor et al (1996)
reporting that telomerase activity in SCC is generally lower than in
other histological types of tumour such as BCC. Hence, titration
experiments with known positive cell extract (HT1080) was regu-
larly performed and were shown to detect telomerase activity in as
few as ten cell equivalents (Figure 2). In addition, the lack of telom-
erase activity could not be explained by inactive protein samples
because all the protein extract samples used in this study had
similar alkaline phosphatase activities. False-negative TRAP assay
results can be caused by the presence of a telomerase or Taq poly-
merase inhibitor, and inhibitors may be naturally present or intro-
duced during sample preparation. To eliminate the possibility of
false-negative results, mixing experiments with a positive control
(HT1080 cells) and the negative cell extracts were performed. Only
one negative SCC sample was identified as a false negative, and its
removal from the data represents a small change in the overall
frequency of telomerase-positive SCC samples (25% ® 27%). In
conclusion, the high proportion of negative SCC samples were not
due to experimental artefact.
In contrast to the SCCs, 69% of CMMs examined were positive
for telomerase. This higher value might be explained by the
greater overall tumour aggression and more frequent metastasis
associated with CMM. In this respect, telomerase activity may be
explained by the concept of ‘mortal’ tumours. In SCCs, in which
there is limited aggression and a lower metastatic rate, the lesion
might be composed of transformed cells that are not immortalized,
thereby explaining the lack of telomerase activity in the majority
of SCC tumours. However, it remains an open question whether
SCCs with telomerase activity are any more aggressive than those
without. Given the phenotype of CMM, it is unlikely that this
would be achieved without immortalization of cells and yet, in a
significant number of CMM samples, telomerase activity was not
detected. For example, in three samples of CMM derived from the
same individual (one primary and two metastatic), telomerase was
not observed, providing strong evidence that the acquisition of
tumorigenic and metastatic potential can be achieved in the
absence of telomerase activity.
Given that we have identified a number of SCC and CMM
samples that lack functional telomerase activity, it was appropriate
to ask what effect the absence of activity had on telomere length. It
was observed that telomere length could not be related to telom-
erase activity (Figures 3 and 4). For example, telomerase-positive
samples were among the tumours with the largest and smallest
mean TRF length (kb). Also, the negative SCC had mean TRFs
ranging from 3.6 to 11 kb. Our data are consistent with the find-
ings of Wainwright et al (1995), who demonstrated that telomere
length varied significantly within samples derived from BCCs
despite the presence of telomerase activity in these tumours.
If telomere stabilization is critical in skin carcinogenesis, it 
may be that mechanisms other than telomerase activation are
involved in telomere maintenance. In the S. cerevisiae mutant
Est1, telomeres are maintained via a recombination pathway 
using subtelomeric elements (Lundblad and Blackburn, 1993).
Moreover, in the yeast Kluyveromyces lactis, telomeres can be
maintained by a RAD52-dependent recombination mechanism
during which telomeric repeat sequences are added, in contrast 
to subtelomeric elements as in S. cerevisiae (McEachern and
Blackburn, 1996). Drosophila, however, can utilize transposable
elements to maintain telomere length (Bryan et al, 1995).
An ALT (alternative lengthening of telomeres) pathway has
been proposed (Murnane et al, 1994; Bryan et al, 1997) to explain
the observation that approximately one-third of in vitro immortal-
ized cell lines and an increasing number of tumour biopsy samples
lack telomerase activity. The precise molecular events of the ALT
pathway are not fully understood, but, in general, cells utilizing
this pathway have long heterogeneous telomeres (Bryan et al,
1997). Three of our telomerase-negative SCCs do not fall into this
category and have relatively short telomeres (3.6, 4.5 and 5.5 kb).
In this respect, the negative SCCs do not fulfil a central criterion of
the ALT pathway.
In summary, we have identified a number of SCC and CMM
samples which are apparently lacking telomerase activity.
Moreover, our data show there is no relationship between telomere
size and telomerase activity in the malignant skin lesions analysed.
These data add to an increasing number of reports in which the
absence of telomerase activity has been associated with tumour
biopsies (e.g. Bryan et al, 1995). This suggests that telomerase-
negative tumour cells can utilize a telomerase-independent
pathway to maintain telomere size. However, the precise means by
which maintenance is achieved remains to be understood.
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